Related Experiment Video
Updated: Jul 8, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report
Anu Dham1, Alexander M Truskinovsky, Arkadiusz Z Dudek
1Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA.
Abstract:
Carcinoids are malignant neuroendocrine tumors consisting of a spectrum of neoplasms from low-grade typical carcinoid to high-grade small cell carcinoma. We report a case of atypical thymic carcinoid that responded to neoadjuvant therapy with octreotide and sunitinib, an oral multikinase inhibitor. After 3 weeks of treatment, tumor size significantly decreased to allow for a safe surgical resection with clear margins. We believe that further study of sunitinib and octreotide with the neoadjuvant intent of preparing tumors for resection is warranted as a strategy to improve curative management of neuroendocrine tumors.
